Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ContraFect Corporation stock

Own ContraFect Corporation stock in just a few minutes.

ContraFect Corporation is a biotechnology business based in the US. ContraFect Corporation shares (CFRX) are listed on the NASDAQ and all prices are listed in US Dollars. ContraFect Corporation employs 33 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in ContraFect Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CFRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ContraFect Corporation share price

Use our graph to track the performance of CFRX stocks over time.

ContraFect Corporation shares at a glance

Information last updated 2021-04-29.
52-week range$3.63 - $8.00
50-day moving average $4.69
200-day moving average $5.25
Wall St. target price$15.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $0.44

Buy ContraFect Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ContraFect Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ContraFect Corporation financials

Gross profit TTM $-1,606,434
Return on assets TTM -49.7%
Return on equity TTM -199.94%
Profit margin 0%
Book value $0.45
Market capitalisation $174.2 million

TTM: trailing 12 months

Shorting ContraFect Corporation shares

There are currently 5.5 million ContraFect Corporation shares held short by investors – that's known as ContraFect Corporation's "short interest". This figure is 21.2% up from 4.5 million last month.

There are a few different ways that this level of interest in shorting ContraFect Corporation shares can be evaluated.

ContraFect Corporation's "short interest ratio" (SIR)

ContraFect Corporation's "short interest ratio" (SIR) is the quantity of ContraFect Corporation shares currently shorted divided by the average quantity of ContraFect Corporation shares traded daily (recently around 1.7 million). ContraFect Corporation's SIR currently stands at 3.28. In other words for every 100,000 ContraFect Corporation shares traded daily on the market, roughly 3280 shares are currently held short.

However ContraFect Corporation's short interest can also be evaluated against the total number of ContraFect Corporation shares, or, against the total number of tradable ContraFect Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ContraFect Corporation's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 ContraFect Corporation shares in existence, roughly 140 shares are currently held short) or 0.172% of the tradable shares (for every 100,000 tradable ContraFect Corporation shares, roughly 172 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ContraFect Corporation.

Find out more about how you can short ContraFect Corporation stock.

ContraFect Corporation share dividends

We're not expecting ContraFect Corporation to pay a dividend over the next 12 months.

Have ContraFect Corporation's shares ever split?

ContraFect Corporation's shares were split on a 1:10 basis on 3 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ContraFect Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for ContraFect Corporation shares which in turn could have impacted ContraFect Corporation's share price.

ContraFect Corporation share price volatility

Over the last 12 months, ContraFect Corporation's shares have ranged in value from as little as $3.63 up to $8. A popular way to gauge a stock's volatility is its "beta".

CFRX.US volatility(beta: 0.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ContraFect Corporation's is 0.9603. This would suggest that ContraFect Corporation's shares are less volatile than average (for this exchange).

ContraFect Corporation overview

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site